|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) |
|---|---|
| Information provided by: | Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) |
| ClinicalTrials.gov Identifier: | NCT00430755 |
Purpose
Aim:
To investigate the quality of history taking with or without an knowledge based interview system.
Patients:
400 inpatients presenting at the RBK for the first time and treated in the departments of nephrology and department of hematology/oncology.
Methods:
The information obtained either by an knowledge based system or by conventional history taking is compared by the patient, by the physician and by independent reviewers. Study endpoint is the percentage of histories missing clinically significant information.
Study procedure After informed consent of the patients the procedure of history taking is performed by the physician according to the guidelines of the RBK. Within 2 days thereafter the patient is interviewed with help of the CLEOS system with the support of a study nurse. The physician will be informed about the results immediately after completion of the questionnaire. Both the patient and the treating physician will rate the comparative quality of the two histories by means of a questionnaire. In addition, the relevance of the differences of the information obtained by the two systems is rated by an independent reviewer.
| Condition | Intervention |
|---|---|
|
Hypertension Diabetes Hypercholesterolemia Vasculitis Coronary Heart Diseases |
Procedure: Computer-assisted history |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study |
| Official Title: | Quality Assessment for History Taking With or Without an Knowledge Based Interview System. |
| Estimated Enrollment: | 1000 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | December 2007 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Dominik M Alscher, MD | +4971181010 ext 5458 | dominik.alscher@rbk.de |
| Germany | |
| Robert-Bosch-Hospital | Recruiting |
| Stuttgart, Germany, 70376 | |
| Principal Investigator: | Dominik M Alscher, MD | Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) |
More Information
| Responsible Party: | Robert Bosch Foundation ( Robert Bosch Hospital ) |
| Study ID Numbers: | RBK080 |
| Study First Received: | January 31, 2007 |
| Last Updated: | July 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00430755 History of Changes |
| Health Authority: | Germany: Ethics Commission |
|
Arterial Occlusive Diseases Metabolic Diseases Heart Diseases Vasculitis Hyperlipidemias Myocardial Ischemia Diabetes Mellitus Vascular Diseases Ischemia |
Arteriosclerosis Coronary Disease Metabolic Disorder Hypercholesterolemia Dyslipidemias Coronary Artery Disease Lipid Metabolism Disorders Hypertension |
|
Arterial Occlusive Diseases Metabolic Diseases Heart Diseases Vasculitis Hyperlipidemias Myocardial Ischemia Vascular Diseases Arteriosclerosis |
Coronary Disease Cardiovascular Diseases Hypercholesterolemia Coronary Artery Disease Dyslipidemias Lipid Metabolism Disorders Hypertension |
